During the past decade, Instituto de Cardiologia do Rio Grande do Sul conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 7 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 5 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto de Cardiologia do Rio Grande do Sul" #1 sponsor was "Instituto de Cardiologia do Rio Grande do Sul" with 19 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Cardiovascular Research Center, Brazil" with 2 trials sponsored, "Eidos Therapeutics, a BridgeBio company" with 2 trials sponsored and "Hospital do Coracao" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Cardiologia do Rio Grande do Sul" #1 collaborator was "Conselho Nacional de Desenvolvimento Científico e Tecnológico" with 4 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator, "Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil" with 3 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "CNPq Universal" with 1 trials as a collaborator. Other collaborators include 10 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "Instituto de Cardiologia do Rio Grande do Sul" are "Heart Failure" (5 trials), "Hypertension" (5 trials), "Coronary Artery Disease" (3 trials), "Cardiovascular Diseases" (2 trials) and "Dilated Cardiomyopathy" (2 trials). Many other conditions were trialed in "Instituto de Cardiologia do Rio Grande do Sul" in a lesser frequency.

Most popular intervention types in "Instituto de Cardiologia do Rio Grande do Sul" are "Drug" (18 trials), "Other" (10 trials), "Dietary Supplement" (5 trials), "Procedure" (4 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Empagliflozin" (3 trials), "Conventional treatment and follow up" (2 trials), "Methotrexate" (2 trials) and "Multidisciplinary assistance" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instituto de Cardiologia do Rio Grande do Sul" are 40 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are 7 active trials in "Instituto de Cardiologia do Rio Grande do Sul". 2 are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 27 completed trials in Instituto de Cardiologia do Rio Grande do Sul, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto de Cardiologia do Rio Grande do Sul, 2 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 15 trials that are defined as “Not Applicable".